• ქართული
  • English
  • Roche enters $1.15 billion licensing deal for Sarepta gene therapy

    Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.

    Market Quotes by TradingView